HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters
- 8 December 2015
- journal article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Surgery
- Vol. 31 (4), 207-213
- https://doi.org/10.5152/ucd.2015.2964
Abstract
Human epidermal growth factor-2 (HER-2) overexpression has prognostic value in breast cancer. However, the significance of HER-2 positivity in gastric cancer is controversial. In this study, we investigated the frequency of overexpression of HER-2 and its relationship with clinicopathological findings and impact on survival in gastric cancer. Gastric cancer patients, operated in Marmara University Faculty of Medicine, Pendik Training and Research Hospital, General Surgery Department, between January 2012-December 2013 were enrolled in this study. Medical records were retrospectively evaluated. Tissue samples were stained by immunohistochemistry (IHC) method, and were followed by fluorescence in situ hybridization (FISH) in those with positive results. HER-2 expression rates and its association with other histopathological features and survival have been analyzed. 135 patients were enrolled in the study, with 88 (65%) male and 47 (35%) female patients. The median age was 61 (29-84) years. Only 11 patients (8%) were positive for HER-2. HER-2 positive patients were similar to negative patients in terms of age, gender, tumor size, tumor location, tumor T stage, lymph node metastasis, histological type, differentiation, lymphovascular invasion, perinodal, perineural invasion and stage. No significant difference was detected on 1 and 2-year overall and disease-free survival rates between receptor positive and negative groups. Consistent with the literature data, HER-2 positivity rate in this study was approximately 8%, but this positivity has not been found to be associated with either clinical and pathological parameters or overall and disease-free survival.Keywords
This publication has 25 references indexed in Scilit:
- Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric CancerClinical Cancer Research, 2012
- Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significanceZeitschrift für Krebsforschung und Klinische Onkologie, 2009
- Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate DataJournal of Clinical Oncology, 2006
- Survival After Gastric Adenocarcinoma Resection: Eighteen-Year Experience at a Single InstitutionJournal of Gastrointestinal Surgery, 2005
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals Of Oncology, 2005
- The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of TherapyThe Oncologist, 2003
- Overexpression of c‐ erb B‐2 protein in gastric cancer. Its correlation with long‐term survival of patientsCancer, 1993
- Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinomaJournal of Surgical Oncology, 1992
- Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.1991
- Published by Stichting OpenAccess Foundation